OVERVIEW

Targeted Pathways in Psoriasis and Psoriatic Arthritis - Implications for Improved Patient Outcomes is organized by CME Outfitters, LLC and will be held from Nov 07, 2018 - Nov 07, 2019.

Target Audience
Rheumatologists, dermatologists, physicians, physician assistants, nurse practitioners, nurses, and pharmacists who treat patients with psoriatic arthritis.

Credit Information
CME Credit (Physicians):
USF Health designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Need
Psoriatic arthritis (PsA) is a serious and potentially disabling condition that effects about 30% of patients with psoriasis. Increased understanding of the pathogenesis of PsA has highlighted the critical importance of the action of several inflammatory cytokines, including tumor necrosis factor (TNF)-α, interleukin (IL)-23, and IL-17 in the development of the disease. However, clinicians often lack a thorough understanding of these molecular targets and drugs designed to target these pathways.

Since 2008, several agents have been FDA-approved for the treatment of PsA, and there are several agents currently under investigation. As clinicians treat patients with PsA, continuing education regarding molecular targets of emerging agents to make informed treatment decisions is needed.

Join CME Outfitters and our expert faculty in this CME Snack for a discussion about PsA treatment strategies and best implementation practices for current and emerging biologic treatment options with a focus on molecular targets.

Learning Objectives
At the end of this CE activity, participants should be able to:
• Identify the molecular targets of currently available and emerging treatments for the management of psoriatic arthritis.

Additional details will be posted as soon as they are available.